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The Belgian surrealist artist Rene Magritte created sev-
eral paintings of mundane elements, arranged to provoke 
a reflection on meaning. In one of his paintings he depicts 
an apple but just above it we read “Ceci n’est pas une pom-
me”. In fact, it is not an apple, but the painting of an apple.
To model is to abstract, to choose the most appro-
priate metaphor or analogy to better understand a phe-
nomenon1. Models are interfaces between humans and 
phenomena2; they are means to represent the complexity 
of the real world in a more simple and understandable 
way.  Apples, whose genome was decoded only in 2010, 
have 17 chromosomes containing approximately 57,000 
genes3 that generate a fruit composed of approximately 
85% water; 14% carbohydrates; very little protein, fiber, 
minerals, and vitamins; interconnected and arranged in 
a three-dimensional structure4. When we see the paint-
ing of an apple, we know it is a simplified but intelligible 
representation, i.e., a model of this complex fruit.
In 1972, the Nuffield Provincial Hospitals Trust, Lon-
don, published a book by Archie Cochrane, “Effective-
ness and efficiency: random reflections on health ser-
vices”, in which the author discusses the basics of what 
is now called evidence-based medicine, health technol-
ogy assessment, and systematic review. In this book, Co-
chrane expressed his perception that there would never 
be enough monetary resources to provide all diagnos-
tic and therapeutic procedures that doctors can invent, 
and therefore, it is imperative to test and validate how 
we invest those resources, derived from public or private 
funds, to ensure reduced morbidity and/or mortality5.
In the last four decades, more intensely in the last 
twenty years, as a result of Cochrane’s ideas, the health-
care professionals’ community learned how to use and 
became accustomed to the format, language, and specific 
aspects (statistical and epidemiological) of the two main 
models that are used in our area of knowledge: clinical 
trials and systematic reviews/meta-analyses.
Clinical trials are models of more complex situations 
faced in everyday life6,7 and meta-analyses are models to 
help us understand the overall results of several clini-
cal trials performed to answer the same specific clinical 
question. We all strive to better and more properly inter-
pret the results of these models, so that we can use them 
in our daily clinical practice.
Indeed, the last two decades have been very fruitful in 
developing new diagnostic and therapeutic technologies 
that are often more effective than those existing but that 
are also more expensive, as envisioned by Cochrane. The 
world has witnessed rapid growth in healthcare costs, 
a problem that plagues low, middle, and high-income 
countries8.
Brazil is no exception. Hence, aiming to regulate, to 
streamline, and to rationalize the process of incorporat-
ing health technologies, in accordance with social needs 
and SUS (Sistema Único de Saúde - Unified Health Sys-
tem) management, Law 12,401 of April 28th, 2011 was 
passed. Resulting from a legislative movement to ratio-
nalize the incorporation of healthcare technologies origi-
nated at the beginning of the last decade, the law requires 
that in order to incorporate a particular technology into 
the SUS it is necessary to prove its cost-effectiveness and 
demonstrate its budget impact9.
The proposition of Law 12,401 is fully in line with Co-
chrane’s thought who forty years ago said that “If we are 
ever going to get the ‘optimum’ results from our national 
expenditure on the National Health Service (NHS) we 
must finally be able to express the results in the form of 
the benefit and the cost to the population of a particular 
type of activity, and the increased benefit that could be 
obtained if more money were made available.”5.
Given the rising costs and limited resources of global 
and national healthcare systems, and the very existence 
of the Law 12,401, we will more frequently find articles 
presenting a pharmacoeconomic evaluation of a medical 
technology in international and Brazilian medical jour-
nals. These assessments are called pharmacoeconomic 
because they take into account not only clinical outcomes 
or consequences but also the cost of a given health tech-
nology, as proposed by Cochrane.
Pharmacoeconomic evaluations may be based on 
the so-called pharmacoeconomic models, which are an 
analytical methodology that considers the occurrence of 
events over time and across populations based on data 
obtained from  primary or secondary sources, whose 
purpose is to estimate the effects of an intervention in 
terms of health consequences and costs. They are mod-
els that help us determine the efficiency of a healthcare 
technology7.
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Thus, to understand the healthcare setting reality in 
which financial resources are limited, and whose proper al-
location is of paramount importance to maximize health 
with the available resources, we have to strive to understand 
and interpret these new pharmacoeconomic models, which 
take into account the clinical and economic aspects of the 
incorporation of a technology into the healthcare system8.
In this issue of RAMB, Nita ME et al.10 present the re-
sults of a pharmacoeconomic model which assesses the 
cost-effectiveness of saxagliptin added to metformin for 
the treatment of type 2 diabetes mellitus in the Brazilian 
private healthcare setting. To critically appraise a pharma-
coeconomic study, Michael Drummond11,12 suggests that 
we analyze ten points: 
1. Was a well-defined question structured in an an-
swerable form?
2. Was a comprehensive description of the competing 
alternatives provided?
3. Are there evidences that the effectiveness of the pro-
gram/technology has been established?
4. Were all the important and relevant costs and 
clinical outcomes identified for each competing 
alternative?
5. Were costs and clinical outcomes measured accu-
rately and in appropriate units?
6. Were costs and outcomes evaluated credibly?
7. Were costs and clinical outcomes adjusted for the 
time of their occurrence (discount)?
8. Was an incremental costs and outcomes analysis 
(clinical consequences) of the competing alterna-
tives accomplished?
9. Was uncertainty taken into account in the estimates 
of costs and consequences?
10. Did the presentation and discussion of study results 
comprise all topics of concern to users?
For the study of Nita ME et al.10 the answer to most of 
these questions is yes. But as with any model, we can always 
deepen the discussion.
In this case, from the medical point of view, we should 
consider the fact that the patients included in the model 
are those who failed to achieve the glycemic control goals. 
Glycemic control, in turn, is affected by adherence to treat-
ment, such that13 regimens where the drug is taken once a 
day have higher rates of adherence than regimens where 
the medicine is taken twice a day14, and monotherapy regi-
mens demonstrate higher adherence rates than polythera-
py regimens15.
What is proposed in this pharmacoeconomic study is 
the addition of another drug to the therapeutic scheme; 
but adherence to treatment is not considered in the model. 
Still, in relation to better glycemic control and adherence 
to therapy, we should consider that other interventions can 
improve adherence to treatment16 and to the system of self-
management, reducing mortality and disability, improv-
ing the quality of life17-19 without adding a new drug to the 
regimen.
Additionally, despite the fact that the model being pre-
sented is based on the United Kingdom Prospective Diabe-
tes Study (UKPDS) model, one of the best to predict long-
term outcomes in patients with diabetes, the latter does not 
include among the complications the occurrence of dia-
betic neuropathy, which is a well-known cause of morbid-
ity, such as lower limb amputation, and reduced quality of 
life20, parameters that, if considered, probably would have 
changed the model’s clinical and economic results.
It is important to note that changing both clinical and 
economic outcomes does not necessarily imply that the 
final conclusion of the study/model would be different. 
Moreover, from the modeling point of view, as the present-
ed model is based on the UKPDS, the risk equations are 
those found for the British population and not yet validated 
for the Brazilian population.
Thus, the need for external validation of the model pre-
sented in this issue of RAMB becomes more important, 
and it can be accomplished by comparing the results pro-
jected in the study, for example, with external epidemio-
logical data not used in this evaluation21. A good agreement 
between the predictions of the simulation and the external 
data would help validate the accuracy of the model, and it 
would be important to infer whether it may or may not rep-
resent the population being simulated.
Finally, the economic evaluation for reimbursement of 
medicines and other healthcare technologies is mandatory 
in many countries, including Brazil. Hence, pharmacoeco-
nomics, with its techniques and models, is here to stay.
As we have seen, there are several challenges to over-
come, mainly related to methodological issues, which, in 
turn, leads us to a more careful analysis and interpreta-
tion of results, because, after all, as Magritte pointed out, 
every time we see an apple painting, we should remem-
ber that this model gives us the illusion that we interpret 
to be “an apple.” But what apple? The technological apple? 
The sin apple? Or, simply, the fruit?
But whatever the apple, there will always be more than 
one picture to represent it.
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